Solís-Olivares CA, Solís-Soto JM

Language: Spanish
References: 22
Page: 64-71
PDF size: 67.26 Kb.

ABSTRACT

Introduction: 60% of the patients treated with coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) suffer from multivessel coronary artery disease. Objective: Our objective was to compare the clinical course of patients with this diagnosis after revascularization. Methods: We consulted and compared the clinical records of a multivessel coronary artery disease cohort treated with either coronary artery bypass grafting or angioplasty with drug eluting stents or bioactive stents between January 2004 and July 2011, consigning adverse cardiovascular events. Results: 134 patients, mostly male, with 3-vessel disease and stable angina, were followed up for 35.7 ± 20.4 months. Dyslipidemia (41.9 vs 36.7%), diabetes mellitus type 2 (59.5 vs 38.3%), hypertension (67.6 vs 60%), old myocardial infarction (37.8 vs 23.3%) and type C lesion in left anterior descendent artery (63.9 vs 30.4%) were all more frequent in the surgery group (p ‹ 0.05). On the other hand, the angioplasty treated patients needed more frequently revascularization (30.50 vs 2.73%; p ‹ 0.01) and hospitalization (25 vs 9%) and had more often angina (44 vs 20%), positive ergometry (39 vs 18%), and functional impairment type New York Heart Association III/IV (22 vs 11%) (p ‹ 0.05). Conclusion: In patients at a community hospital with multivessel coronary artery disease, PCI has a higher recurrence of ischemia and repeated revascularization compared to CABG.

REFERENCES

1. Sabik JF. CABG or PCI? A cardiothoracic surgeon’s perspective. The devil (or truth) is in the details. Clev Clin J Med 2006; 73: 329-338.

2. Klein LW. Are drug-eluting stents the preferred treatment for multivessel coronary artery disease? J Am Coll Cardiol 2006; 47: 22-26.

3. Tsigkas GG, Karantalis V, Hahalis G, Alexopoulos D. Stent restenosis, patophysiology and treatment options: a 2010 update. Hell J Cardiol 2011; 52: 149-157.

4. Serruys PW, Unger F, Sousa JE, Jatene A et al. Arterial revascularization therapies study group. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001; 344: 1117-1124.

5. Unger F. Drug eluting stents– a nightmare? Interact Cardiovasc Thorac Surg 2007; 6: 813-814.

6. Carrizo G, Pocovi A, Tajer C. Seguridad de los stents liberadores de droga. Rev Argent Cardiol 2007; 75: 207-214.

7. Hoffman SN, TenBrook JA, Wolf MP, Pauker SG, Salem DN, Wong JB. A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: one–to eight–year outcomes. J Am Coll Cardiol 2003; 41: 1293-1304.

8. SoS Investigators. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the stent or surgery trial): a randomized controlled trial. Lancet 2002; 360: 965-970.

9. Rodríguez A, Bernardi V, Navia J, Baldi J et al. Argentine randomized study: coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple-vessel disease (ERACI II); 30-day and one-year follow-up results. J Am Coll Cardiol 2001; 37: 51-58.

10. Serruys PW, Ong AT, Morice MC, De Bruyne B et al. Arterial revascularization therapies study part II: Sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions. Eurointervention 2005; 1: 147-156.

11. Serruys PW, Morice MC, Kappetein AP, Colombo A et al. SYNTAX investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360: 961-972.

12. Kappetein AP, Feldman TE, Mack MJ, Morice MC, Holmes DR, Stahle E et al. Comparison if coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J 2011; 32: 2125-134.

13. Hannan EL, Wu C, Waldford G, Culliford AT et al. Drug-eluting stents vs coronary-artery bypass grafting in multivessel coronary disease. N Eng J Med 2008; 358: 331-341.

14. Kapur A, Hall RJ, Malik IS, Qureshi AC et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-Year results of the CARDia (coronary artery revascularization in diabetes) trial. J Am Coll Cardiol 2010; 55: 432-440.

15. Boden WE, O’Rourke RA, Teo KK, Hartigan PM et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356: 1503-1516.

16. Frye RL, August P, Brooks MM, Hardison RM et al. BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360: 2503-2515.

17. Fuster V. De la enfermedad multivaso compleja a la salud cardiovascular. Rev Esp Cardiol 2010; 63(Supl 2): 3-11.

18. Applegate RJ, Sacrinty MT, Kutcher MA, Santos RM, Gandhi SK, Baki TT et al. “Off-label” stent therapy, 2-Year comparison of drug-eluting versus bare metal stents. J Am Coll Cardiol 2008; 51: 607-614.

19. Fernández AJ. Stents liberadores de fármacos: reestenosis intrastent. Rev Fed Arg Cardiol 2010; 39: 319-323.

20. Pijls NH, van Shaardenburgh P, Manoharan G, Boersma E, Bech JW, van’tVeer M et al. Percutaneous coronary intervention of functionally non significant stenosis. 5-year follow-up of the DEFER study. J Am Coll Cardiol 2007; 49: 2105-2111.

21. Beller GA, Ragosta M. Decision making in multivessel coronary disease: the need of physiological lesion assessment. J Am Coll Cardiol Intv 2010; 3: 315-317.

22. Massoudy P, Thielmann M, Lehmann N, Marr A, Kleikamp G, Maleszka A et al. Impact of prior percutaneous intervention on the outcome of coronary artery bypass surgery: a multicenter analysis. J Thorac Cardiovasc Surg 2009; 137: 840-845.